Harrow Health price target raised to $37 from $24 at Lake Street

Lake Street analyst Brooks O’Neil raised the firm’s price target on Harrow Health to $37 from $24 and keeps a Buy rating on the shares. 2022 was "a transformational year for Harrow" and the firm believes the company – which has affirmed guidance for at least $135M of revenue and at least $44M of AEBITDA this year – is "poised to deliver strong growth in 2023," the analyst tells investors.